The Relationship Between ICER and Industry is Evolving

The relationship between pharma and the Institute for Clinical and Economic Review (ICER) has seen evolution, since ICER began ruling on the clinical and economic value of drugs, medical devices and other healthcare interventions. Of the 79 treatments that ICER… Read »

Driving CAR-T beyond oncology

CAR-T cell therapies – T cells tagged with chimeric antigen receptors – have only been on the market for a couple of years, but have already been hailed as a game changer in the treatment of some cancers, and even… Read »

FDA Policy Changes Spur Spate of New Diabetes Collaborations

Effective diabetes care is a complex, information-rich daily challenge. Besides lowering blood glucose levels, patients need to cope with the risk of hypoglycemia, manage the effects of their dietary choices and activity levels, and monitor the potential side-effects associated with… Read »

ESMO 2019: Translating Science into Better Cancer Care

The field of oncology has seen a number of significant advances in recent years. The considerable number of positive reports from the 2019 Congress of the European Society for Medical Oncology (ESMO) last month clearly reflected the meeting’s theme —… Read »

Psychedelic Drug Research Making a Comeback

In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological… Read »

Long Awaited CMS Rules on Medicare Coverage for CAR-T Therapies

In August, the Centers for Medicare and Medicaid Services (CMS) finalized long-sought rules framing the coverage of chimeric antigen receptor T-cell (CAR-T) treatments. Two CAR-T therapeutics are currently on the market: Gilead’s Yescarta and Novartis’ Kymriah, both approved for diffuse… Read »

New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer

Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its… Read »

Expanding the CRISPR Toolbox for New Healthcare Applications

CRISPR/Cas9 was first successfully demonstrated as a tool for genome editing in human cells in 2013.  Since then, several advances have enabled the use of this technology to shut down a faulty gene, change a single DNA letter in a… Read »

New Approvals for Tumor-Agnostic Cancer Treatments — and the Questions They Raise

On August 15, the U.S. Food and Drug Administration granted accelerated approval to Genentech/Roche’s Rozlytrek (entrectinib) for the treatment of adult and adolescent patients with solid tumors that exhibit neurotrophic tyrosine receptor kinase (NTRK) fusions and for whom there are… Read »

The Missing Piece in the Brexit Prep Jigsaw

After three years since the United Kingdom’s vote to leave the European Union and a number of extensions, the country is fast approaching the latest deadline of October 31, 2019. The new Prime Minister, Boris Johnson, and the leaders of… Read »

1 2 3 4 19